The Use of Opioids for Breakthrough Pain in Acute Palliative Care Unit by Using Doses Proportional to Opioid Basal Regimen

ObjectivesTo determine the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP). MethodsIn 66 patients consecutive patients admitted to a pain relief and palliative care unit, the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP) were assessed. The choice of the opioid to be administered as rescue medication was based on the characteristics of patients, clinical stability, compliance, preference, and so on. For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (T0), and to re-assess the patient 15 minutes after the opioid given as a rescue medication (T15). ResultsSix hundred twenty four episodes of BP were recorded during admission. Intravenous morphine (IV-MO) and oral transmucosal fentanyl (OTFC) were most frequently administered. Of 503 events available, 427 episodes were defined as successfully treated, while 76 episodes required a further administration of opioids. Pain intensity significantly decreased at T15 in all the groups (P<0.001). In 97.2% and 90.7% of cases treated with IV-MO, BP events had a reduction in pain intensity of more than 33% and 50%, respectively. In 99.2% and 97.6% patients receiving OTFC, BP events had a reduction in pain intensity of more than 33% and 50%, respectively. DiscussionThis survey suggests that doses of opioids for BP proportional to the basal opioid regimen, are very effective and safe in clinical practice, regardless the opioid and modality used.

[1]  S. Mercadante Breakthrough pain: On the road again , 2009, European journal of pain.

[2]  G. Zeppetella Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. , 2008, Journal of pain and symptom management.

[3]  A. Davies,et al.  An observational study of oncology patients' utilization of breakthrough pain medication. , 2008, Journal of pain and symptom management.

[4]  S. Mercadante,et al.  Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. , 2008, Journal of pain and symptom management.

[5]  S. Mercadante,et al.  Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain , 2007, British Journal of Cancer.

[6]  J. Farrar,et al.  A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. , 2007, Journal of palliative medicine.

[7]  J. Farrar,et al.  Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. , 2006, Journal of pain and symptom management.

[8]  S. Mercadante,et al.  Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. , 2004, Journal of pain and symptom management.

[9]  R. Portenoy,et al.  Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®) , 2001, Pain.

[10]  E. Kalso,et al.  Morphine and alternative opioids in cancer pain: the EAPC recommendations , 2001, British Journal of Cancer.

[11]  Jesse A. Berlin,et al.  Defining the clinically important difference in pain outcome measures , 2000, PAIN.

[12]  Paul Jacobsen,et al.  Breakthrough pain: characteristics and impact in patients with cancer pain , 1999, Pain.

[13]  R. Portenoy,et al.  Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study , 1999, PAIN.

[14]  M. Simmonds,et al.  Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Farrar,et al.  Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. , 1998, Journal of the National Cancer Institute.

[16]  R. Portenoy,et al.  Breakthrough pain: definition, prevalence and characteristics , 1990, Pain.